EUCTR2007-002631-86-SK进行中（未招募）不适用
A phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment for at least 5 days with a parenteral anticoagulant approved for this indication. RE-COVER II - RE-COVER II
Boehringer Ingelheim Pharma Ges mbH0 个研究点目标入组 2,550 人开始时间: 2008年6月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,550
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Acute symptomatic uni- or bilateral DVT of the leg involving proximal veins, and/or
- •PE confirmed by definitive objective clinical test in patients for whom at least 6 months of anticoagulant therapy is considered appropriate by the investigator
- •2. Male or female, being 18 years of age or older
- •3. Written informed consent for study participation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Overt symptoms of VTE for longer than 2 weeks prior to enrolment
- •2. PE satisfying at least one of the following criteria:
- •Haemodynamic instability
- •Embolectomy is indicated or performed
- •Thrombolytic therapy is indicated or performed
- •Suspected source of PE is other than the legs
- •3. Actual or anticipated use of vena cava filter
- •4. Contraindications to anticoagulant therapy including contraindications to heparins or other alternate approved therapy used for initial treatment, and warfarin
- •5. Patients who in the investigator’s opinion should not be treated with warfarin
- •6. Allergy to heparins (including history of heparin induced thrombocytopenia) or other alternate approved therapy used for initial treatment, warfarin or dabigatran, or to one of the excipients included in these medications
- •7. In case of anticipated study related diagnostic procedures requiring contrast medium:
- •Elevated serum creatinine, which in the investigator’s opinion contraindicates
- •these examinations
- •Known allergy to radio opaque contrast media or iodine, which in the
- •investigator’s opinion contraindicates these examinations
- •8. Patients who in the investigator’s judgement are perceived as having an excessive risk of bleeding (examples listed in the protocol)
- •9. Known anaemia (haemoglobin < 100 g·L-1)
- •10. Need of anticoagulant treatment for disorders other than VTE
- •11. Recent unstable cardiovascular disease, such as uncontrolled hypertension at the time of enrolment (investigator’s judgement), acute bacterial endocarditis or history of myocardial infarction within the last 3 months
- •12. Elevated Aspartate-aminotransferase (AST) or Alanine-aminotransferase (ALT) > 3xULN based on the local lab results obtained at screening and prior to randomisation
- •13. Liver disease expected to have any potential impact on survival (e.g. acute hepatitis, possibly active hepatitis B, hepatitis C or cirrhosis, but not Gilbert’s syndrome or hepatitis A with complete recovery)
- •14. Severe renal impairment (estimated creatinine clearance = 30 ml/min)
- •15. Women who are pregnant, nursing, or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study
- •16. Patients considered unsuitable for inclusion by the investigator, e.g. because
- •considered unreliable to comply with the requirements for follow-up during the study
- •and/or compliance with study drug administration, has a life expectancy less than the
- •expected duration of the trial due to concomitant disease, or has any condition which
- •in the opinion of the investigator would not allow safe participation in the study (e.g.,
- •drug addiction, alcohol abuse)
- •17. Participation in another clinical trial with an investigational drug during the last 30
- •days or previous participation in this study or RE-COVER I (1160.53)
研究者
相似试验
进行中（未招募）
1 期
A phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment for at least 5 days with a parenteral anticoagulant approved for this indication. RE-COVER II - RE-COVER IIAcute symptomatic VTEVTE is defined as the composite incidence of Deep Vein Thrombosis of the leg (including the inferior caval vein) and Pulmonary Embolism.MedDRA version: 9.1Level: LLTClassification code 10037377Term: Pulmonary embolismMedDRA version: 9.1Level: LLTClassification code 10047251Term: Venous thrombosis deep (limbs)EUCTR2007-002631-86-NLBoehringer Ingelheim Pharma GmbH & Co KG2,550
进行中（未招募）
1 期
A phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment (5-10 days) with a parenteral anticoagulant approved for this indication. RE-COVER - RE-COVEREUCTR2005-001999-12-GBBoehringer Ingelheim Ltd.2,550
进行中（未招募）
不适用
A phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment (5-10 days) with a parenteral anticoagulant approved for this indication. RE-COVER - RE-COVERAcute symptomatic venous thromboembolism (VTE), i.e. uni- or bilateral deep vein thrombosis (DVT) of the leg involving proximal veins, and/or pulmonary embolism (PE) confirmed by definitive objective clinical testEUCTR2005-001999-12-DKBoehringer Ingelheim BV2,550
进行中（未招募）
不适用
A phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment for at least 5 days with a parenteral anticoagulant approved for this indication. RE-COVER II - RE-COVER IIAcute symptomatic VTEVTE is defined as the composite incidence of Deep Vein Thrombosis of the leg (including the inferior caval vein) and Pulmonary Embolism.MedDRA version: 9.1Level: LLTClassification code 10037377Term: Pulmonary embolismMedDRA version: 9.1Level: LLTClassification code 10047251Term: Venous thrombosis deep (limbs)EUCTR2007-002631-86-HUBoehringer Ingelheim RCV GmbH & Co KG2,550
进行中（未招募）
不适用
A phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment for at least 5 days with a parenteral anticoagulant approved for this indication. RE-COVER II - RE-COVER IIAcute symptomatic VTEVTE is defined as the composite incidence of Deep Vein Thrombosis of the leg (including the inferior caval vein) and Pulmonary Embolism.MedDRA version: 9.1Level: LLTClassification code 10037377Term: Pulmonary embolismMedDRA version: 9.1Level: LLTClassification code 10047251Term: Venous thrombosis deep (limbs)EUCTR2007-002631-86-SEBoehringer Ingelheim AB2,550